Development of a potent small‐molecule degrader against oncogenic BRAFV600E protein that evades para...
Development of a potent small‐molecule degrader against oncogenic BRAFV600E protein that evades paradoxical MAPK activation
About this item
Full title
Author / Creator
Publisher
Oxford, UK: Blackwell Publishing Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Oxford, UK: Blackwell Publishing Ltd
Subjects
More information
Scope and Contents
Contents
BRAF mutations are frequently observed in melanoma and hairy‐cell leukemia. Currently approved rapidly accelerated fibrosarcoma (RAF) kinase inhibitors targeting oncogenic BRAF V600 mutations have shown remarkable efficacy in the clinic, but their therapeutic benefits are occasionally hampered by acquired resistance due to RAF dimerization–dependen...
Alternative Titles
Full title
Development of a potent small‐molecule degrader against oncogenic BRAFV600E protein that evades paradoxical MAPK activation
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9357609
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9357609
Other Identifiers
ISSN
1347-9032
E-ISSN
1349-7006
DOI
10.1111/cas.15401
